ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 1687

The Risk of Atrial Fibrillation in Patients with Rheumatoid Arthritis Compared to the General Population: A Large Cohort Study

Seoyoung C. Kim1, Jun Liu2 and Daniel H. Solomon3, 1Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, 3Division of Rheumatology, Brigham and Women's Hospital, Boston, MA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: Cardiovascular disease and rheumatoid arthritis (RA)

Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Rheumatoid Arthritis and Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:  It is well-known that rheumatoid arthritis (RA) is associated with cardiovascular disease such as myocardial infarction. However, little evidence exists on the risk of atrial fibrillation (AF) in patients with RA. The objective of this study was to estimate the incidence rates (IR) and rate ratios (RR) of AF among patients with RA compared to those without RA.

Methods: We conducted a large population-based cohort study using the US commercial insurance claims data. The RA cohort included adults with at least two diagnoses of RA and at least one prescription for a disease-modifying anti-rheumatic drug (DMARD). Subjects who never had a diagnosis of RA matched on age, sex, and index date with a 5:1 ratio were selected as a comparison cohort. Follow-up began with the first prescription for a DMARD for RA patients and the 2nd physician visit date for non-RA patients after a 12-month baseline period. Patients with history of any cardiac arrhythmia, cardiovascular surgery and anticoagulant users during the baseline period were excluded.  Primary outcome was an inpatient diagnosis of AF and secondary outcome was an outpatient or inpatient diagnosis combined with a dispensing of anticoagulant within 10 days after the first diagnosis of AF. We calculated IRs and RRs of AF with 95% confidence intervals (CI). Multivariable Cox proportional hazards models compared the risk of AF between RA and non-RA patients.

Results: The study population included 20,891 RA and 104,455 non-RA patients. Mean (SD) age was 52 (12) years and 74% were women. During a mean follow-up of 2 years, 0.8% of RA patients and 0.6% non-RA patients developed AF as inpatient. Table shows the IRs for primary outcome and secondary outcome.  The RR was 1.4 (95% CI, 1.2-1.7) for primary and 1.3 (95% CI, 1.0-1.6) for secondary outcome in RA patients, compared to age- and sex- matched subjects without RA.  After adjusting for comorbidities such as cardiovascular disease and thyroid disease, various medications and health care utilization characteristics, the risk of AF was not increased in RA (hazard ratio 1.0, 95% CI: 0.8-1.3) compared to non-RA patients.

Conclusion: Our results showed that the incidence of AF was similar in both RA and non-RA patients. The risk of AF was not increased in patients with RA compared to non-RA patients after adjusting for various comorbid conditions and medications.

Table. Incidence rates per 1,000 person-years (95% confidence interval) and rate ratios (95% confidence interval) of atrial fibrillation (AF) in patients with and without rheumatoid arthritis (RA).

RA

Non-RA

Age- and sex-matched RR

Fully adjusted RR

Inpatient AF

4.1 (3.5-4.8)

2.9 (2.7-3.2)

1.4 (1.2-1.7)

1.0 (0.8-1.3)

Inpatient and outpatient AF with an anticoagulant dispensing

2.6 (2.2-3.2)

2.1 (1.9-2.3)

1.3 (1.0-1.6)

1.0 (0.7-1.3)


Disclosure:

S. C. Kim,

Pfizer Inc,

2,

Takeda Pharmaceuticals,

2;

J. Liu,
None;

D. H. Solomon,

Amgen & Lilly,

2,

Corrona,

5,

Pfizer Inc,

2.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-of-atrial-fibrillation-in-patients-with-rheumatoid-arthritis-compared-to-the-general-population-a-large-cohort-study/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology